NASDAQ: NKTRNektar Therapeutics Revenue
Nektar Therapeutics revenue was $98.43M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $29.2M, up 20.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NKTR annual revenue was $98.4M, with 9.2% growth year-over-year.
NKTR past revenue growth
How has NKTR's revenue growth performed historically?
Company
9.22%
Industry
437.31%
Market
20.27%
NKTR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NKTR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NKTR's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
NKTR revenue history
Current Revenue
$98.4M
Current Earnings
-$119.0M
Current Profit Margin
-120.9%
Be the first to know when NKTR announces revenue.
NKTR Revenue History By Year
| NKTR Yearly Revenue | NKTR Revenue | NKTR Change | NKTR Revenue Growth |
|---|---|---|---|
| 2024-12-31 | $98.43M | $8.31M | +9.22% |
| 2023-12-31 | $90.12M | -$1.93M | -2.10% |
| 2022-12-31 | $92.06M | -$9.85M | -9.67% |
| 2021-12-31 | $101.91M | -$51.01M | -33.36% |
| 2020-12-31 | $152.92M | $38.30M | +33.41% |
| 2019-12-31 | $114.62M | -$1.08B | -90.40% |
| 2018-12-31 | $1.19B | $885.61M | +287.81% |
| 2017-12-31 | $307.71M | $142.28M | +86.00% |
| 2016-12-31 | $165.44M | -$65.35M | -28.32% |
| 2015-12-31 | $230.78M | $30.08M | +14.99% |
| 2014-12-31 | $200.71M | $51.79M | +34.77% |
| 2013-12-31 | $148.92M | $67.73M | +83.42% |
| 2012-12-31 | $81.19M | $9.71M | +13.59% |
| 2011-12-31 | $71.48M | -$87.56M | -55.06% |
| 2010-12-31 | $159.04M | $87.11M | +121.10% |
| 2009-12-31 | $71.93M | -$18.25M | -20.24% |
| 2008-12-31 | $90.19M | -$182.84M | -66.97% |
| 2007-12-31 | $273.03M | $55.31M | +25.40% |
| 2006-12-31 | $217.72M | $91.44M | +72.41% |
| 2005-12-31 | $126.28M | $12.01M | +10.51% |
| 2004-12-31 | $114.27M | $8.01M | +7.54% |
| 2003-12-31 | $106.26M | $11.41M | +12.03% |
| 2002-12-31 | $94.85M | $17.38M | +22.43% |
| 2001-12-31 | $77.47M | $25.84M | +50.05% |
| 2000-12-31 | $51.63M | $10.27M | +24.83% |
| 1999-12-31 | $41.36M | $19.56M | +89.76% |
| 1998-12-31 | $21.80M | $5.55M | +34.13% |
| 1997-12-31 | $16.25M | $9.36M | +135.83% |
| 1996-12-31 | $6.89M | $3.45M | +100.00% |
| 1995-12-31 | $3.45M | $1.79M | +108.66% |
| 1994-12-31 | $1.65M | N/A | N/A |
Nektar Therapeutics Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.